Clinical Trials Logo

Cardiometabolic Diseases clinical trials

View clinical trials related to Cardiometabolic Diseases.

Filter by:
  • None
  • Page 1

NCT ID: NCT06426082 Not yet recruiting - Clinical trials for Cardiometabolic Diseases

Deciphering a Novel and Unique Brown Adipose Tissue Depot in Women

DEBATE
Start date: November 1, 2024
Phase: N/A
Study type: Interventional

Type of Study: Clinical Trial Goal: The goal of this clinical trial is to investigate specific brown and beige fat cells in the dorsocervical area of young, lean adult women. Participant Population/Health Conditions: The study will involve 40 young, lean adult women. Main Questions: The main questions this study aims to answer are: - Are there active brown or beige adipocytes in the subcutaneous fat of the dorsocervical area (i.e., iBAT)? - What is the secretory function of these adipocytes? - How do traditional interventions like cold exposure, as well as new approaches like Beta-2 agonist stimulation and exercise, affect the thermogenesis of these fat cells at the cellular and molecular levels? Participants Will: Be randomized into one of four groups: thermoneutral exposure, cold exposure, aerobic exercise, or Beta-2 agonist treatment. Follow their assigned regimen for 4 weeks. Provide tissue samples from the dorsocervical area and abdomen before and after the 4-week intervention. Undergo analysis of these samples using advanced techniques to understand the presence and activity of brown and beige fat cells. Comparison Group: Researchers will compare the effects of different interventions (thermoneutral exposure, cold exposure, aerobic exercise, Beta-2 agonist treatment) on the presence and thermogenesis of brown and beige fat cells in the dorsocervical area.

NCT ID: NCT06336005 Recruiting - Healthy Volunteers Clinical Trials

A Study to See How Safe a New Medicine (NNC6022-0001) is in Healthy People

Start date: March 28, 2024
Phase: Phase 1
Study type: Interventional

The study is testing a new study medicine, which is being tested as a potential medicine to treat cardiometabolic diseases. The aim of this study is to see if the study medicine is safe, how it works in participants body, and what the body does to the study medicine. Participants will either get NNC6022-0001 (the new study medicine) or placebo (a "dummy medicine" without the active ingredient). Which treatment participants get is decided by chance. The study medicine is a potential new medicine which cannot be prescribed by doctors. The study will last for about 10 months in total.

NCT ID: NCT05256251 Recruiting - Aging Clinical Trials

Westlake Longevity Cohort

We-Longevity
Start date: November 15, 2021
Phase:
Study type: Observational [Patient Registry]

The Westlake Longevity Cohort (We-Longevity) is a prospective cohort study among centenarians, nonagenarians, senior citizens and their family members up to three generations living in Lishui, China. The primary aim of this cohort is to characterize the multi-omics molecular characteristics of healthy longevity and their dynamic trajectories. Another aim of We-Longevity is to investigate the association of dietary and lifestyle with the multi-omics molecular characteristics of healthy longevity, and to facilitate the development of personalized nutritional/lifestyle recommendation for the public.

NCT ID: NCT05223530 Recruiting - Obesity Clinical Trials

Prenatal Programming of Childhood Obesity and Cardio Metabolic Disorders

Start date: February 25, 2022
Phase:
Study type: Observational [Patient Registry]

This is a prospective 11-17 -years follow-up of two existing pregnancy cohort (PREDO) and prevention (RADIEL) studies. The main objective is to investigate the associations between maternal overweight, obesity, hypertensive disorders in pregnancy, gestational diabetes, and maternal-fetal metabolome, child's birth outcomes, and overweight and obesity and cardio metabolic health outcomes in childhood and adolescence. During this follow-up study, the mothers and their 11-17-year-old children are invited for a study visit and their cardio metabolic health is studied by many different methods.

NCT ID: NCT05216042 Recruiting - Obesity Clinical Trials

GENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study

Start date: April 1, 2022
Phase: N/A
Study type: Interventional

Natriuretic Peptides (NP) are hormones produced by the heart, and they have a wide range of favorable metabolic benefits. Lower levels of these hormones are associated with an increased likelihood of the development of diabetes and poor cardiometabolic health. Obese and Black individuals have ~30% lower levels of NP and are at a greater risk of developing cardiovascular (CV) events as compared to lean and White counterparts. Some people have common genetic variations that cause them to have ~20% lower NP levels. Similar to other low NP populations, these individuals with low NP genotype (i.e., carrying a common genetic variation called rs5068) are at a greater risk of developing cardiometabolic diseases. By understanding the NP response following the exercise challenge and the glucose challenge in individuals with genetically lower NP levels will help us understand how to improve cardiometabolic health in them.

NCT ID: NCT04940598 Completed - Clinical trials for Spinal Cord Injuries

High Intensity Interval Exercise SCI

Start date: February 1, 2021
Phase: N/A
Study type: Interventional

This study will determine if the implementation of a home-based telehealth high intensity interval exercise-training (HIIT)program can significantly improve cardiometabolic health and physical function in a cohort of individuals with longstanding spinal cord injury (SCI). Results from this study will determine feasibility, overall enjoyment, and health impact of implementing a home-based telehealth HIIT program in individuals with SCI.

NCT ID: NCT04271735 Completed - Obesity Clinical Trials

Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis

Start date: August 26, 2020
Phase: N/A
Study type: Interventional

Background: Psoriasis causes chronic inflammation in the body. Researchers want to see if a kind of vitamin B3 dietary supplement can help. This might lead to more treatment options. Objective: To test if the dietary supplement nicotinamide riboside can improve immune system function in the blood and skin of people with mild to moderate psoriasis. Eligibility: People ages 18-80 with mild to moderate active psoriasis not currently treated with biological therapy Design: Participations will be screened with: - Medical and medication history - Physical exam - Measure of body mass index - Skin exam - Blood and urine tests Participants will have visit 1. They will have repeats of the screening tests. They may also have 2 skin biopsies, which are optional. These will be from both lesions and unaffected areas. The areas will be injected with a numbing medicine. A round cutting device will remove small pieces of skin from each area. Participants will take the study supplement or a placebo starting at the first visit. Neither participants nor the study team will know which they receive. Participants will take capsules twice daily for a total of 4 weeks. Participants will then have visit 2. This will include the tests performed at visit 1. Participants may by contacted by phone or email between visits to see how they are doing. If participants develop any side effects in the 7 days after they stop taking the capsules, they may have another visit.